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Abstract
Background: To investigate how serum neurofilament light (NfL) concentration changes through the course of
disease in familial Alzheimer’s disease (FAD) and to assess when NfL concentration first increases.
Methods: NfL was measured using an ultrasensitive immunoassay in 117 serum samples from 61 individuals from
families with PSEN1 or APP mutations in a longitudinal study (mean ± SD = 1.9 ± 1.1 visits/patient; inter-visit interval
= 1.8 ± 1.1 years). The relationship between NfL concentration and estimated years to/from symptom onset (EYO)
was modelled using linear regression, including all time points and robust standard errors to allow for repeated
measurements, adjusting for age at visit and sex. Also, for the 27 participants who became symptomatic (during or
before the study), NfL concentration was also modelled against known actual years to/from onset (AYO).
Results: There were 15 non-carriers and 46 mutation carriers (21 symptomatic; 25 presymptomatic). NfL concentration
was increased (p = 0.045) in mutation carriers compared with non-carriers 15 years prior to expected symptom onset,
increasing progressively thereafter. There was a significant inter- and intra-individual variability in the longitudinal
pattern of change. Modelling NfL for the 27 mutation carriers with known AYO also showed a progressive
increase over time.
Conclusions: There is evidence that serum NfL is increased more than a decade before the onset of clinical symptoms
in FAD and rises thereafter. While there is variability in change over time, both within and between individuals, and more
work is needed to understand the sources of this variability, serum NfL remains a promising, accessible biomarker of early
neurodegeneration in presymptomatic Alzheimer’s disease.
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Background
Biomarkers sensitive to early neurodegeneration in Alzhei-
mer’s disease (AD) can facilitate early diagnosis, monitor
disease progression, and support trials of potential
disease-modifying therapies. A blood-based biomarker
would be less invasive and likely cheaper than currently
available imaging and cerebrospinal fluid measures. We
previously reported that the concentration of serum
neurofilament light (NfL) in autosomal dominant famil-
ial Alzheimer’s disease (FAD) mutation carriers was in-
creased prior to the onset of clinical symptoms [1].
Serum NfL has also been shown to be closely associated
with validated imaging and cognitive measures of early
neurodegeneration [1, 2].
However, it remains uncertain when in relation to
symptom onset, serum NfL first increases. Also, while
clinically important phenotypic differences have been
found within the spectrum of FAD, particularly between
amyloid precursor protein (APP) and presenilin 1
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(PSEN1) mutation carriers, and within the PSEN1 gene
between mutations located pre and post-codon 200 [3],
it is unknown whether this heterogeneity translates to
differences in NfL concentration.
We therefore carried out a longitudinal study, with an
increased sample size, of serum NfL in FAD mutation
carriers and mutation-negative relatives.
Methods
Participants
We recruited 61 participants from 30 FAD families to a
longitudinal study of FAD at the Dementia Research
Centre, University College London, between April 2010
and February 2018. Eligibility was either (i) clinical diag-
nosis of FAD or (ii) an FAD-affected parent. Twenty-one
participants were symptomatic, with pathogenic muta-
tions in the PSEN1 or APP genes; 40 were asymptomatic
but at 50% risk of an inherited mutation and thereby of
developing symptoms at a similar age to their parent.
Genetic test data on the presence or absence of a mu-
tation in ‘at-risk’ participants were provided only to
study statisticians. Estimated years to/from symptom on-
set (EYO) were calculated by subtracting parental age of
onset of progressive cognitive symptoms from the par-
ticipant’s current age. At each study visit, procedures
undertaken included blood sampling, a semi-structured
health questionnaire (including exclusion of recent head
injury), neurological examination, and the clinical de-
mentia rating scale.
In total, 117 serum samples were obtained and one
third of participants (20/61) had three or more time
points (mean ± SD per participant 1.92 ± 1.08). The
mean ± SD inter-visit interval was 1.75 ± 1.09 years. An
ultrasensitive immunoassay on the Simoa platform
measured serum NfL, using a methodology described
previously [4]. All samples were processed according to
the same standardised operating procedure and mea-
sured as duplicates. Samples from all time points were
also processed concurrently using the same kit and
batch of reagents to maximise consistency of analyses.
Coefficients of variation (CVs) for duplicate concentra-
tions of subject samples and quality control (QC) sam-
ples were < 15%.
Following genetic testing, we found that there were
a total of 46 mutation carriers (21 symptomatic and
25 presymptomatic) and 15 non-carriers in the study.
The total number of serum samples from each group
was 29 from the symptomatic mutation carriers, 54
from the presymptomatic carriers, and 36 from the
non-carriers.
Statistical analysis
Summary baseline descriptive data were calculated for
symptomatic mutation carriers, presymptomatic mutation
carriers, and non-carriers, and observed NfL concentra-
tions plotted for carriers and non-carriers. For several par-
ticipants, there were large within-person changes in NfL
concentrations over relatively short time intervals. This
meant that although we had longitudinal data, we have
not analysed it in a way that explicitly models longitudinal
change within subjects because the large within-person
variability in observed rates of change created conver-
gence problems when we tried to fit a mixed effects
model. Instead, a linear regression model was used,
including all time points and robust (Huber-White)
standard errors that allowed for repeated measure-
ments within individuals [5, 6]. The dependent variable
(NfL) was log-transformed, and the relationship with
EYO was modelled using genetic mutation status and
linear, quadratic and cubic terms for EYO, plus their in-
teractions with mutation status, as predictor variables,
adjusting for age at visit and sex. The estimated geo-
metric mean longitudinal NfL concentration profiles
for the two groups (and 95% confidence intervals) were
plotted against EYO standardising to the mean age and
gender mix in the sample. We estimated the difference
in geometric mean NfL for values of EYO between − 20
and 10 years, adjusted for age at visit and sex, and
tested for when the difference between carriers and
non-carriers was statistically significantly different from
zero (p < 0.05).
Separately, for 27 participants who became symptom-
atic (before or during the study), NfL concentration
was plotted against actual years to/from onset (AYO),
rather than EYO. Non-carriers do not have AYO values,
so for comparison, we used their mean serum NfL con-
centration ± 1.96SD to provide a 95% reference range),
calculated on the log scale and back-transformed. For
the 27 symptomatic carriers, NfL was modelled against
AYO, using linear regression with robust standard er-
rors as above; the quadratic and cubic terms for AYO
were not statistically significant so were dropped, with
only the linear term for AYO being significant. Non-
carriers were not included in the AYO model. The
modelled geometric mean longitudinal NfL concentra-
tion profile (and its 95% confidence interval) for symp-
tomatic mutation carriers was plotted against AYO,
with the same standardisation for age and gender as in
the EYO graphs for consistency. In this case for com-
parison with non-carriers, we used the non-carrier geo-
metric mean serum NfL concentration and its 95%
confidence interval.
Separate models compared mean log NfL in PSEN1
versus APP carriers and, in PSEN1 carriers, compared
those with mutations pre- versus post-codon 200. These
models adjusted for age at visit, sex, and EYO, and uti-
lised robust standard errors. All analyses used Stata v15
(StataCorp, College Station, TX, USA).
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Results
Participants’ demographic details and serum NfL values
are in Table 1 and Fig. 1a. For mutation carriers, 37 had
mutations in PSEN1 and nine in APP (Additional file 1:
Table S1).
Estimated differences in NfL concentration between
the two groups showed that NfL concentration was
significantly increased (p = 0.045) in mutation carriers
compared with non-carriers 15 years prior to expected
symptom onset, after adjusting for age at visit and sex,
and diverged progressively thereafter (Fig. 1b). Model-
ling NfL for the 27 mutation carriers with known AYO
showed a progressive increase over the disease period
that these data cover, consistent with the EYO-based
analysis (Fig. 2).
Across all participants, adjusting for age at visit, sex,
and EYO, there was no significant difference in NfL
values between PSEN1 carriers and APP carriers (p =
0.63). In PSEN1, there was no significant difference in
NfL concentration between individuals with mutations
pre and post-codon 200 (p = 0.67).
Discussion
This study supports the utility of serum NfL as a poten-
tial biomarker of early neurodegeneration in presymp-
tomatic AD. We extend previous findings by showing
that not only is NfL concentration increased in presymp-
tomatic FAD, but also this increase first occurs more
than a decade before the onset of clinical symptoms and
continues to rise thereafter.
Serum NfL has been associated with validated cogni-
tive and structural imaging markers of disease severity
in AD (Fig. 2) [1, 2, 7], including whole-brain volume,
atrophy rates, and the MMSE. However, the initial
change in NfL in our study appears to occur before
these other measures are first thought to become abnor-
mal [8, 9]. While markers of molecular pathology (i.e.
CSF Aβ1–42 and amyloid PET) have been previously
shown to change as early or earlier than markers of neu-
rodegeneration [9–11], Aβ alone is not sufficient to
cause symptomatic AD; therefore, downstream markers
of neuronal loss are vital in helping identify those who
are closest to symptom onset [12].
The comparatively early change in NfL compared to
other validated markers of neurodegeneration, com-
bined with the relative accessibility and
non-invasiveness of a blood-based measure, suggests
the potential utility of NfL as a screening measure in
presymptomatic trials, and possibly even in the general
population if disease-modifying treatments were to be-
come available. However, our sample is relatively
young, and it would therefore be important to assess
how serum NfL varies between presymptomatic AD
and healthy ageing in older individuals (i.e. the age
range more relevant to sporadic AD) before any such
more general use could be considered.
In mutation carriers, within-person longitudinal meas-
urement of NfL generally demonstrates progressive in-
crease with increasing follow-up time. There is, however,
significant inter- and intra-individual variability, with
some people exhibiting large changes over relatively
short time intervals. Sample processing is unlikely to ac-
count for this variability as subject and QC samples were
analysed in a consistent manner and QC CV between
plates was less than 5%. NfL is a relatively non-specific
marker of neuronal damage, and increases can be seen
with neurodegeneration and also with neuroinflamma-
tion [1, 4, 13]. Coexistence of these pathological
processes in FAD may be partly responsible for fluctua-
tions seen in NfL concentration. Equally there may also
Table 1 Participant demographics and serum NfL concentration. For variables with missing data points, the number of observations
is shown underneath the group average value (e.g. n = x). EYO estimated years to/from onset, MMSE Mini-Mental State Examination,
CDR Clinical Dementia Rating Scale, SOB sum of boxes
Non-carriers
N = 15
Presymptomatic
N = 25
Symptomatic
N = 21
Gender (female/male) 11/4 13/12 7/14
Age (mean, SD) 39.7 (9.1) 36.2 (5.8) 47.4 (9.3)
EYO (years) (mean, SD) n/a − 9.25 (6.21) 3.09 (3.53)
MMSE (median, IQR) 30 (30–30) 30 (29–30) 23 (19.5–26.5)
(n = 20)
CDR Global (median, IQR) 0 (0–0) 0 (0–0) 0.5 (0.5–1.0)
(n = 18)
CDR SOB (median, IQR) 0 (0–0) 0 (0–0) 3.25 (1.5–4.5)
(n = 18)
Baseline NfL (pg/mL)
(mean, SD)
10.34 (7.62) 12.83 (6.71) 22.60 (12.28)
Annualised rate of change in NfL (pg/mL/years) (mean, SD)* 0.51 (1.54)
(n = 9)
0.67 (3.72)
(n = 17)
3.52 (3.72)
(n = 5)
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be physiological factors that have an effect. Further in-
vestigation, and improved understanding, of confound-
ing causes of alterations in NfL concentration is needed
before this biomarker can be used in clinical practice.
EYO based on parental age at onset is a relatively
reliable proxy measure of proximity to symptom onset
[14]. However, EYO carries a degree of error, so using
AYO when known may provide additional accuracy. As
with the EYO-based model, analysis based on AYO
shows progressive increase as individuals approach and
then pass expected onset. The consistency between
these models confirms that NfL is a marker of pre-
symptomatic neurodegeneration and remains elevated
after the onset of symptoms.
PSEN1 carriers have been reported to have more wide-
spread atrophy patterns in the early stages of disease
progression than APP carriers [15]. However, after
adjusting for age at visit, sex and disease stage (i.e.
EYO), we found no difference in NfL concentration be-
tween PSEN1 and APP carriers. Also, although PSEN1
Fig. 1 Serum NfL against EYO. Mutation carriers are represented in red and non-carriers in black. a Measured values of serum NfL concentration
against EYO. Those measurements that belong to the same individual are connected by a line. To ensure it is not possible to identify any of the
individual asymptomatic participants (based on their EYO) and so determine their mutation status, five outlying participants have been removed
and a jitter of up to ± 2 years has been applied to all remaining participants. Also, for the three individuals who donated more than three
samples, only their first three measurements are shown. b Geometric mean NfL modelled against EYO, for someone of average age (40.9 years)
and sex (half male/female). Dotted lines indicate 95% confidence intervals. EYO estimated years to/from symptom onset. The geometric mean is
the exponential of a mean calculated on the log scale
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mutations located post-codon 200 often have more com-
plex clinical phenotypes than those pre-codon 200, this
did not translate to a difference in NfL.
Our study has limitations. The sample size was lim-
ited, owing primarily to the relative rarity of FAD muta-
tions, and replication, especially of sub-group analyses,
is required in larger cohorts. Given the sample size and
the degree of fluctuation in NfL concentrations, it was
not possible reliably to model rate of change over time
within subjects. Also, due to the reliance on EYO, it is
difficult to say with certainty the precise time point that
NfL first increases. Further assessment of serum NfL in
presymptomatic sporadic AD will also be important.
Conclusions
We show that serum NfL is already increasing early in
the presymptomatic phase of FAD and rises progres-
sively thereafter. It will be important for the sources of
intra-individual variability over time to be understood.
Fig. 2 Serum NfL against AYO. a (In red) measured serum NfL concentration against AYO, for the 27 mutation carriers who have already developed
symptoms (either before or during the study). Those measurements that belong to the same individual are connected by a line. No jitter has been
applied. The black broken line represents the mean serum NfL concentration for non-carriers, with dotted lines for ± 1.96 SD, calculated on the log
scale and back transformed. By showing ± 1.96 SD, we are indicating a reference range within which 95% of the observed values are expected to lie. b
Geometric mean NfL modelled against AYO, for someone of average age (40.9 years) and sex (half male/female). The black broken line represents the
geometric mean serum NfL concentration for non-carriers. Dotted lines indicate 95% confidence intervals (i.e. on repeated random sampling, 95% of
CIs calculated in this way will include the true population geometric mean). AYO actual years to/from symptom onset. The geometric mean is the
exponential of a mean calculated on the log scale
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Overall, however, serum NfL is a promising, easily ac-
cessible marker of early neurodegeneration in AD.
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